OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as TRANCE, RANKL and ODF) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit defects in early differentiation of T and B lymphocytes. Surprisingly, opgl-deficient mice lack all lymph nodes but have normal splenic structure and Peyer's patches. Thus OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and is an essential osteoclast differentiation factor in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor B ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“In the absence of RANK or RANKL, osteoclasts cannot form, function, or survive (62-64, 110, 111).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“RANK and RANKL knockout mice were virtual phenocopies of each other (62)(63)(64), which indicated that RANK and RANKL had few if any roles beyond their mutual interactions.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Another unexpected phenotype found in RANK and RANKL knockout mice was the total lack of lymph nodes (62,64).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Examination of mice genetically deficient in RANKL, RANK, or OPG also revealed no overt dendritic cell defects (62,64,170).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P., Montgomery, C., Geske, R., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 2,016
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Self-citationManolagas, S. C., & Jilka, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320506 · Cited by 1,668
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.
Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., Maraskovsky, E., Gliniak, B. C., Park, L. S., Ziegler, S. F., Williams, D. E., Ware, C. B., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.5.1955 · Cited by 1,555
c-Fos: a Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone Remodeling
Grigoriadis, A. E., Wang, Z.-Q., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., & Wagner, E. F. (1994) · Science · doi:10.1126/science.7939685 · Cited by 1,260
Cited by
Items 301–400 of 1,030
INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES
Baru, P. C. R. (2014) · ADVANCED SCIENCES INDEX · Cited by 236
Shakibaei, M., Buhrmann, C., & Mobasheri, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.198713 · Cited by 226
Updates on Osteoimmunology: What's New on the Cross-Talk Between Bone and Immune System
Ponzetti, M., & Rucci, N. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00236 · Cited by 221
Osteoprotegerin and RANK ligand expression in prostate cancer.
Brown, J. M., Corey, E., Lee, Z. D., True, L. D., Yun, T. J., Tondravi, M., & Vessella, R. L. (2001) · Urology · doi:10.1016/s0090-4295(00)01122-5 · Cited by 234
The aging of the immune system
Grubeck-Loebenstein, B., & Wick, G. (2002) · Advances in Immunology · doi:10.1016/s0065-2776(02)80017-7 · Cited by 234
Invited Review: Pathogenesis of osteoporosis
Seeman, E. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00564.2003 · Cited by 222
“Genetic ablation of RANKL results in osteopetrosis because RANKL is necessary for normal osteoclast formation (36).”
BackgroundArterial calcification: A review of mechanisms, animal models, and the prospects for therapy
Wallin, R., Wajih, N., Greenwood, G. T., & Sane, D. C. (2001) · Medicinal Research Reviews · doi:10.1002/med.1010 · Cited by 235
“Mice lacking OPG-L lack osteoclasts and develop severe osteopetrosis.(74) Transgenic mice that overexpress OPG and those lacking RANK also have defective osteoclastogenesis and an osteopetrosis phenotype.”
BackgroundFu, Q., Jilka, R. L., Manolagas, S. C., & O'Brien, C. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208494200 · Cited by 227
Lincoln, J., Lange, A. W., & Yutzey, K. E. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.03.027 · Cited by 231
NF-κB modulators in osteolytic bone diseases
Xu, J., Wu, H. F., Ang, E. S. M., Yip, K., Woloszyn, M., Zheng, M. H., & Tan, R. X. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.11.007 · Cited by 229
“Mice deficient in rankl gene exhibit severe osteopetrosis, defective in tooth eruption, and completely lack osteoclasts because of impaired osteoclastogenesis [7].”
BackgroundGenetic control of skeletal development
Wagner, E. F., & Karsenty, G. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00228-8 · Cited by 229
Effects of the IL-23–IL-17 pathway on bone in spondyloarthritis
Gravallese, E. M., & Schett, G. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0091-8 · Cited by 223
Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure
Ueland, T., Yndestad, A., Øie, E., Florholmen, G., Halvorsen, B., Frøland, S. S., Simonsen, S., Christensen, G., Gullestad, L., & Aukrust, P. (2005) · Circulation · doi:10.1161/01.cir.0000165119.62099.14 · Cited by 227
Dual Modulation of Osteoclast Differentiation by Lipopolysaccharide
Zou, W., & Bar-Shavit, Z. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1211 · Cited by 219
Kim, S., Yamazaki, M., Zella, L. A., Shevde, N. K., & Pike, J. W. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00353-06 · Cited by 222
“Perhaps most persuasive is the finding through deletion studies in mice that the loss of either RankL or its receptor (Rank) results in a significant deficiency in osteoclast production (20, 37).”
BackgroundIchikawa, H., Takada, Y., Shishodia, S., Jayaprakasam, B., Nair, M. G., & Aggarwal, B. B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0096 · Cited by 225
“has been implicated as a major mediator of bone resorption (49).”
BackgroundRole of RANKL and RANK in bone loss and arthritis
Jones, D. H., Kong, Y.-Y., & Penninger, J. M. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii32 · Cited by 223
“As both RANKL and RANK are expressed on chondrocytes, 3 15 and rankl 4 as well as rank mutant mice 19 exhibit significant changes in the columnar alignment of chondrocytes at the growth plate, it is possible that RANKL/RANK play a direct part in cartilage growth and cartilage homeostasis.”
BackgroundSelf-citationThe mutational spectrum of human malignant autosomal recessive osteopetrosis
Sobacchi, C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.17.1767 · Cited by 226
RANKing Intracellular Signaling in Osteoclasts
Feng, X. (2005) · IUBMB Life (International Union of Biochemistry and Molecular Biology: Life) · doi:10.1080/15216540500137669 · Cited by 219
“Both RANKL and RANK are essential for the osteoclas-togenic process since mice lacking the gene for either protein developed osteopetrosis due to failure to form osteoclasts ( 10, 11 ).”
BackgroundLIU, W., & ZHANG, X. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3152 · Cited by 216
Bone Aging, Cellular Senescence, and Osteoporosis
Pignolo, R. J., Law, S. F., & Chandra, A. (2021) · JBMR Plus · doi:10.1002/jbm4.10488 · Cited by 201
“gerin (OPG), a decoy receptor that binds RANKL and is secreted by osteoblasts, osteocytes, B lymphocytes, and the liver.((6,11))”
BackgroundNovel host response therapeutic approaches to treat periodontal diseases
Kirkwood, K. L., Cirelli, J. A., Rogers, J. E., & Giannobile, W. V. (2007) · Periodontology 2000 · doi:10.1111/j.1600-0757.2006.00166.x · Cited by 208
“Osteoprotegerin over-expressing or RANKL-/- mice resulted in osteopetrosis (92,161).”
BackgroundLi, P., Schwarz, E. M., O'Keefe, R. J., Ma, L., Boyce, B. F., & Xing, L. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301233 · Cited by 220
“and RANKL are the only requirements for osteoclastogenesis,((4,5)) and mice genetically deficient in M-CSF or c-Fms((6,7)) or RANKL or RANK((8,9)) are incapable of osteoclastogenesis”
BackgroundMin, J.-K., Kim, Y.-M., Kim, S. W., Kwon, M.-C., Kong, Y.-Y., Hwang, I. K., Won, M. H., Rho, J., & Kwon, Y.-G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.1.531 · Cited by 210
Self-citationFarrugia, A. N., Atkins, G. J., To, L. B., Pan, B.-Q., Horvath, N., Kostakis, P., Findlay, D. M., Bardy, P., & Zannettino, A. C. W. (2003) · PubMed · Cited by 242
Potential role of the intestinal microbiota of the mother in neonatal immune education
Donnet-Hughes, A., Perez, P. F., Doré, J., Leclerc, M., Levenez, F., Benyacoub, J., Serrant, P., Segura-Roggero, I., & Schiffrin, E. J. (2010) · Proceedings of the Nutrition Society · doi:10.1017/s0029665110001898 · Cited by 215
“The TNF-family molecule receptor activator of NF-kB ligand (osteoprotegerin ligand, TNFrelated activation-induced cytokin and osteoclast differentiation factor) and its receptor activator of NF-kB are key regulators of bone remodelling((25)) and regulate T-cell/ DC differentiation communication((26,27)), lymph node fo…”
The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis
Mentaverri, R., Yano, S., Chattopadhyay, N., Petit, L., Kifor, O., Kamel, S., Terwilliger, E. F., Brazier, M., Brown, E. M., Mentaverri, R., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6304fje · Cited by 213
“The actual existence of osteoclasts appears to be dependent on RANK-RANKL signaling, since mice lacking either the RANK or the RANKL genes appear to be devoid of osteoclasts (4, 6).”
BackgroundOsteoimmunology: Crosstalk Between the Immune and Bone Systems
Nakashima, T., & Takayanagi, H. (2009) · Journal of Clinical Immunology · doi:10.1007/s10875-009-9316-6 · Cited by 216
“[18, 35, 42, 43, 88, 119] [19, 40, 120] [20, 21, 41, 121] [122] [22, 23, 42, 43, 123] [124]”
BackgroundYu, W., Zhong, L., Yao, L., Wei, Y., Gui, T., Li, Z., Kim, H., Holdreith, N., Jiang, X., Tong, W., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140214 · Cited by 208
“Tnfsf11–/– mice have no osteoclasts in bone and exhibit a severe osteopetrosis (high bone mass) phenotype (4, 5).”
BackgroundOsteoclasts, Master Sculptors of Bone
Veis, D. J., & O'Brien, C. A. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-040919 · Cited by 193
HOROWITZ, M., XI, Y., WILSON, K., & KACENA, M. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00030-7 · Cited by 217
Requirement of NF-κB/Rel for the development of hair follicles and other epidermal appendices
Schmidt-Ullrich, R., Aebischer, T., Hülsken, J., Birchmeier, W., Klemm, U., & Scheidereit, C. (2001) · Development · doi:10.1242/dev.128.19.3843 · Cited by 216
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
“RANKL knockout mice on the other hand revealed an increased bone mass (osteopetrosis) and impaired tooth eruption because of a lack of mature osteoclasts (13).”
BackgroundIkeda, T., Kasai, M., Utsuyama, M., & Hirokawa, K. (2001) · Endocrinology · doi:10.1210/endo.142.4.8070 · Cited by 215
Cellular and molecular basis of tooth eruption
Wise, G. (2009) · Orthodontics & Craniofacial Research · doi:10.1111/j.1601-6343.2009.01439.x · Cited by 211
“In the absence of either CSF-1, as seen in osteopetrotic rats that have defective CSF-1 (27) or in the absence of RANKL, as seen in knockout mice (28), teeth do not erupt.”
BackgroundVoskaridou, E., & Terpos, E. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05143.x · Cited by 208
“& Penninger, J.M. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.”
BackgroundInteraction between osteoblast and osteoclast: impact in bone disease.
Phan, T. C. A., Xu, J., & Zheng, M. (2004) · PubMed · doi:10.14670/hh-19.1325 · Cited by 206
Chronic inflammation in biomaterial-induced periprosthetic osteolysis: NF-κB as a therapeutic target
Lin, T.-H., Tamaki, Y., Pajarinen, J., Waters, H. A., Woo, D. K., Yao, Z., & Goodman, S. B. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.09.034 · Cited by 210
“stasis [96–98].”
BackgroundRANKL/OPG; Critical role in bone physiology
Martin, T. J., & Sims, N. A. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9308-6 · Cited by 213
“Osteopetrotic mice deficient in RANK signaling have absent teeth because of failure of tooth eruption [29].”
BackgroundInfluentialLiu, B., Yu, S., & Li, T. (2003) · Journal of Oral Pathology & Medicine · doi:10.1034/j.1600-0714.2003.00126.x · Cited by 215
Hofbauer, L. C., Shui, C., Riggs, B. L., Dunstan, C. R., Spelsberg, T. C., O'Brien, T., & Khosla, S. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4130 · Cited by 211
Self-citationOSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice
Barrow, A. D., Raynal, N., Andersen, T. L., Slatter, D. A., Bihan, D., Pugh, N., Cella, M., Kim, T., Rho, J., Negishi-Koga, T., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45913 · Cited by 207
Binder, N. B., Niederreiter, B., Hoffmann, O., Stange, R., Pap, T., Stulnig, T. M., Mack, M., Erben, R. G., Smolen, J. S., & Redlich, K. (2009) · Nature Medicine · doi:10.1038/nm.1945 · Cited by 206
“This was shown particularly in RANK- or RANKL-deficient mice, which completely lack osteoclasts and are incapable of generating a normal bone structur”
BackgroundLi, P., Schwarz, E. M., O'Keefe, R. J., Ma, L., Looney, R. J., Ritchlin, C. T., Boyce, B. F., & Xing, L. (2004) · Arthritis & Rheumatism · doi:10.1002/art.11419 · Cited by 205
Kim, M. S., Yang, Y.-M., Son, A., Tian, Y. S., Lee, S.-I., Kang, S. W., Muallem, S., & Shin, D. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.051557 · Cited by 208
Canon, J. R., Roudier, M., Bryant, R., Morony, S., Stolina, M., Kostenuik, P. J., & Dougall, W. C. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9127-1 · Cited by 209
Self-citationPositive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis
Braun, T., & Zwerina, J. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3380 · Cited by 201
The origins and homeostasis of monocytes and tissue‐resident macrophages in physiological situation
Zhao, Y., Zou, W., Du, J., & Zhao, Y. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26461 · Cited by 156
Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis
Söderström, K., Stein, E., Colmenero, P., Purath, U., Müller-Ladner, U., Teixeira de Matos, C., Tarner, I. H., Robinson, W. H., & Engleman, E. G. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000546107 · Cited by 196
“Conversely, mutation or gene ablation of M-CSF (6), RANKL (7), or RANK (8) or overexpression of OPG (9) leads to increased bone thickness and decreased capacity to generate osteoclasts.”
BackgroundRANK, RANKL and osteoprotegerin in bone biology and disease
Wright, H. L., McCarthy, H. S., Middleton, J., & Marshall, M. J. (2009) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-009-9046-7 · Cited by 194
“The axial skeleton (skull, vertebrae, sternum, breastbone and ribs) when visualized by X-ray showed a large increase in radio-density, 516 mg cm in RANKL -/- mice compared with 242 mg cm in RANKL ?/ ? mice [5].”
BackgroundResultInfluentialBasso, K., Liso, A., Tiacci, E., Benedetti, R., Pulsoni, A., Foa, R., Di Raimondo, F., Ambrosetti, A., Califano, A., Klein, U., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031175 · Cited by 206
RANKL Inhibition Through Osteoprotegerin Blocks Bone Loss in Experimental Periodontitis
Jin, Q., Cirelli, J. A., Park, C. H., Sugai, J. V., Taba, M., Kostenuik, P. J., & Giannobile, W. V. (2007) · Journal of Periodontology · doi:10.1902/jop.2007.070073 · Cited by 198
Mak, K. K., Bi, Y., Wan, C., Chuang, P.-T., Clemens, T., Young, M., & Yang, Y. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.02.003 · Cited by 202
“, 1998), and RANKL-deficient mice are osteopetrotic due to the lack of osteoclast differentiation (Kim et al., 2000; Kong et al., 1999).”
BackgroundThe biology of progesterone receptor in the normal mammary gland and in breast cancer
Obr, A. E., & Edwards, D. P. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.10.030 · Cited by 189
“However, it is expressed in a wide variety of other tissues and was subsequently shown in RANKL deficient mice to be required for cellular proliferation, survival and alveologenesis of mammary gland during pregnancy (Dougall et al., 1999; Fata et al., 2000; Kong et al., 1999).”
BackgroundWalsh, M. C., & Choi, Y. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00027-3 · Cited by 200
“Transfer of WT bone marrow into neonatal trance−/− mice does not result in lymph node genesis, suggesting that the source of the defect may lie in a non-hematopoietic cell, and/or be irreversibly established during embryonic development [65].”
BackgroundInfluentialDiscriminating gene expression profiles of memory B cell subpopulations
Ehrhardt, G. R. A., Hijikata, A., Kitamura, H., Ohara, O., Wang, J.-Y., & Cooper, M. D. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072682 · Cited by 198
The Blimp1–Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis
Miyauchi, Y., Ninomiya, K., Miyamoto, H., Sakamoto, A., Iwasaki, R., Hoshi, H., Miyamoto, K., Hao, W., Yoshida, S., Morioka, H., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091957 · Cited by 199
“Osteoclasts originate from BM–derived monocyte/macrophage precursor cells of hema topoietic origin and are differentiated by sig naling through the receptor activator of NFB ligand (RANKL; Kong et al., 1999).”
BackgroundWeih, F., & Caamaño, J. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00064.x · Cited by 201
Michael, H., Härkönen, P. L., Väänänen, H. K., & Hentunen, T. A. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050803 · Cited by 200
“RANKL, a membrane-bound molecule, is a member of the TNF ligand family and has been shown to be crucial for osteoclast formation and activation.((6,7)) Two receptors for RANKL have been identified: RANK, a membrane-bound”
BackgroundZiolkowska, M., Kurowska, M., Radzikowska, A., Luszczykiewicz, G., Wiland, P., Dziewczopolski, W., Filipowicz‐Sosnowska, A., Pazdur, J., Szechinski, J., Kowalczewski, J., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10388 · Cited by 200
The role of the nuclear hormone receptor RORγt in the development of lymph nodes and Peyer's patches
Eberl, G., & Littman, D. R. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00074.x · Cited by 192
“osteoprotegrin ligand (OPGL)] (32), for its receptor”
Yago, T., Nanke, Y., Ichikawa, N., Kobashigawa, T., Mogi, M., Kamatani, N., & Kotake, S. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22326 · Cited by 197
“In addition, we and other groups have detected RANKL in synovial tissue and fluids from patients with RA [Kong et al., 1999; Gravallese et al., 2000; Kotake et al., 2001].”
ResultProstate Carcinoma Skeletal Metastases: Cross-talk between Tumor and Bone
Keller, E. T., Zhang, J., Cooper, C. R., Smith, P. C., McCauley, L. K., Pienta, K. J., & Taichman, R. S. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1015599831232 · Cited by 198
“Both soluble and membrane bound RANKL promote osteoclast formation and activation by binding to RANK on the osteoclast precursor membrane [189–193].”
BackgroundExpression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell Tumors
Atkins, G. J., Haynes, D. R., Graves, S. E., Evdokiou, A., Hay, S., Bouralexis, S., & Findlay, D. M. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.640 · Cited by 197
Sabino, M. A. C., Ghilardi, J. R., Jongen, J. L. M., Keyser, C. P., Luger, N. M., Mach, D. B., Peters, C. M., Rogers, S. D., Schwei, M. J., Felipe, C. D., et al. (2002) · PubMed · Cited by 199
Goëb, V., & Anne-Priscille, T. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s10153 · Cited by 179
“7,8 RANK, the receptor of RANKL, as with OPG, is a receptor from the TNF family.”
Multiple myeloma in the marrow: pathogenesis and treatments
Fairfield, H., Falank, C., Avery, L., & Reagan, M. R. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13038 · Cited by 183
The Potential of Probiotics as a Therapy for Osteoporosis
Collins, F. L., Rios-Arce, N. D., Schepper, J. D., Parameswaran, N., & McCabe, L. R. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0015-2016 · Cited by 184
Influence of Iron on Bone Homeostasis
Balogh, E., Paragh, G., & Jeney, V. (2018) · Pharmaceuticals · doi:10.3390/ph11040107 · Cited by 184
The TNF-? transgenic mouse model of inflammatory arthritis
Li, P., & Schwarz, E. M. (2003) · Springer Seminars in Immunopathology · doi:10.1007/s00281-003-0125-3 · Cited by 191
“[46], the investigators demonstrated that administration of OPG into an adjuvant arthritic model prevents bone and cartilage destruction, while not affecting synovial inflammation.”
Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity
Lam, J., Nelson, C. A., Ross, F. P., Teitelbaum, S. L., & Fremont, D. H. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13890 · Cited by 194
The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease
Kiechl, S., Werner, P., Knoflach, M., Furtner, M., Willeit, J., & Schett, G. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.6.801 · Cited by 195
Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis
Yeo, L., Toellner, K.-M., Salmon, M., Filer, A., Buckley, C. D., Raza, K., & Scheel-Toellner, D. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.153312 · Cited by 191
Cao, J. J., Wronski, T. J., Iwaniec, U., Phleger, L., Kurimoto, P., Boudignon, B., & Halloran, B. P. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050503 · Cited by 195
A role for TGFβ1 in osteoclast differentiation and survival
Fuller, K., Lean, J. M., Bayley, K. E., Wani, M. R., & Chambers, T. J. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.13.2445 · Cited by 199
Yun, T. J., Tallquist, M. D., Aicher, A., Rafferty, K. L., Marshall, A. J., Moon, J. J., Ewings, M. K., Mohaupt, M., Herring, S. W., & Clark, E. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.1482 · Cited by 195
“RANKL, like OPG, regulates final stages of osteoclast differentiation (8, 9, 11, 12).”
BackgroundInfluentialYamaguchi, M., & Fukasawa, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052388 · Cited by 174
Osteoprotegerin diminishes advanced bone cancer pain.
Luger, N. M., Honoré, P., Sabino, M., Schwei, M. J., Rogers, S. D., Mach, D. B., Clohisy, D. R., & Mantyh, P. W. (2001) · PubMed · Cited by 211
Structure and Development of the Skeleton
Marks, S. C., & Odgren, P. R. (2002) · Principles of Bone Biology · doi:10.1016/b978-012098652-1.50103-7 · Cited by 160
Saika, M., Inoue, D., Kido, S., & Matsumoto, T. (2001) · Endocrinology · doi:10.1210/endo.142.6.8220 · Cited by 194
The role of T cells in periodontal disease: homeostasis and autoimmunity
Gemmell, E., Yamazaki, K., & Seymour, G. J. (2007) · Periodontology 2000 · doi:10.1111/j.1600-0757.2006.00173.x · Cited by 189
Overview of RAW264.7 for osteoclastogensis study: Phenotype and stimuli
Kong, L., Smith, W., & Hao, D. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14277 · Cited by 177
Interplay between interferon and other cytokine systems in bone metabolism
Takayanagi, H., Sato, K., Takaoka, A., & Taniguchi, T. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00337.x · Cited by 191
“In fact, the targeted disruption of RANKL results in defective formation of the lymph nodes and lymphocyte differentiation as well as osteopetrosis, a sclerotic bone disease caused by impaired osteoclastic bone resorption (13).”
BackgroundIL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB
Abu-Amer, Y. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10530 · Cited by 188
“RANKL, a transmembrane protein, and its cleaved soluble form have been shown to be effective in inducing osteoclast differentiation through binding to its receptor RANK in osteoclast progenitors (11, 12).”
BackgroundBone loss: Factors that regulate osteoclast differentiation - an update
Roux, S., & Orcel, P. (2000) · Arthritis Research & Therapy · doi:10.1186/ar127 · Cited by 196
Yago, T., Nanke, Y., Kawamoto, M., Furuya, T., Kobashigawa, T., Kamatani, N., & Kotake, S. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2297 · Cited by 193
“In addition, we and other groups have detected RANKL in synovial tissue and fluids from patients with RA [3,36,37].”
BackgroundHofbauer, L. C., Neubauer, A., & Heufelder, A. E. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3<460::aid-cncr1344>3.0.co;2-d · Cited by 215
The role of T lymphocytes in bone metabolism
Weitzmann, M. N., & Pacifici, R. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00324.x · Cited by 192
“RANKL is also capable of activating mature OCs, thus stimulating the capacity of these cells to resorb bone.”
BackgroundInfluentialThe RANK/RANKL/OPG triad in cancer-induced bone diseases
Dougall, W. C., & Chaisson, M. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9021-3 · Cited by 187
Santini, D., Schiavon, G., Vincenzi, B., Gaeta, L., Pantano, F., Russo, A., Ortega, C., Porta, C., Galluzzo, S., Armento, G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019234 · Cited by 185
“The TNF ligand superfamily member RANKL, which is expressed on the surface of osteoblasts, is critical for the formation, function and survival of osteoclasts [2,3].”
BackgroundMechanisms of Disease: the link between RANKL and arthritic bone disease
Schett, G., Hayer, S., Zwerina, J., Redlich, K., & Smolen, J. S. (2005) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0036 · Cited by 191
“One breakthrough was the discovery of RANKL and its receptor RANK”
BackgroundChemokines in lymphopoiesis and lymphoid organ development
Ansel, K. M., & Cyster, J. G. (2001) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00201-6 · Cited by 184
Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention
Karmakar, S., Kay, J., & Gravallese, E. M. (2010) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2010.03.003 · Cited by 186
“Osteoprotegerin (OPG), a decoy receptor for RANKL that is synthesized by osteoblast-lineage cells, acts as a key negative regulator of osteoclastogenesis by binding soluble RANKL and preventing its binding to its receptor RANK, thereby inhibiting osteoclast differentiation (10, 20).”
Polymorphisms in the Osteoprotegerin Gene Are Associated With Osteoporotic Fractures
Langdahl, B. L., Carstens, M., Stenkjaer, L., & Eriksen, E. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1245 · Cited by 191
“RANKL lack osteoclasts and have severe osteopetrosis.((43,44)) Therefore, it has been suggested that it is the ratio”
BackgroundEffects of endogenous sex hormones on the periodontium — Review of literature
Güncü, G., Tözüm, T., & Çaglayan, F. (2005) · Australian Dental Journal · doi:10.1111/j.1834-7819.2005.tb00352.x · Cited by 186
Weitzmann, M. N. (2017) · Toxicologic Pathology · doi:10.1177/0192623317735316 · Cited by 177
“Much of these cytokines emanate from activated immune cells, and animal studies have demonstrated that conditional loss of RANKL production in the adjuvant-induced osteoporosis animal model of RA protects mice from bone loss (Kong et al. 1999).”
BackgroundDickkopf Homolog 1 Mediates Endothelin-1-Stimulated New Bone Formation
Clines, G. A., Mohammad, K. S., Bao, Y., Stephens, O. W., Suva, L. J., Shaughnessy, J. D., Fox, J. W., Chirgwin, J. M., & Guise, T. A. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0346 · Cited by 179
“IL-6, IL-11 and RANKL are potent osteoclast-activating agents (60-62).”
BackgroundKim, K., Kim, H., Park, J., Park, J., Oh, H., Woo, Y., Park, M., Cho, M., & Lee, S. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33446 · Cited by 181
Biggs, T. E., Baker, S. T., Botham, M. S., Dhital, A., Barton, C. H., & Perry, V. H. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200107)31:7<2060::aid-immu2060>3.0.co;2-l · Cited by 53
Inherited disorders of NF-κB-mediated immunity in man
Puel, A., Picard, C., Ku, C.-L., Smahi, A., & Casanova, J.-L. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2003.11.013 · Cited by 186
Metadata
- Authors
- Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., & Penninger, J. M.
- Affiliations
- University of Toronto (CA)
- Amgen (United States) (US)
- Corresponding author
- Penninger, Josef M.
- Venue
- Nature
- Published
- 1999-01
- Volume
- 397
- Issue
- 6717
- Pages
- 315-323
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1534645474
- Cited by
- 3,351
- References
- 52
- Citations by year
- 2026: 27 · 2025: 47 · 2024: 58 · 2023: 71 · 2022: 88 · 2021: 114 · 2020: 121 · 2019: 102 · 2018: 95 · 2017: 115 · 2016: 107 · 2015: 125 · 2014: 119 · 2013: 138 · 2012: 162
- FWCI
- 49.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- osteoprotegerin ligand, RANKL, osteoclastogenesis, osteopetrosis, tooth eruption, lymphocyte development, dendritic cells, T cell development, B cell development, osteoblasts
- MeSH terms
- Animals, B-Lymphocytes, Carrier Proteins, Cell Differentiation, Cells, Cultured, Dendritic Cells, Female, Embryonic and Fetal Development, Growth Substances, Hematopoiesis, Extramedullary, Hematopoietic Stem Cells, Lymph Nodes, Lymphocyte Activation, Lymphocytes, Male, Membrane Glycoproteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Molecular Sequence Data, Osteoclasts, Osteogenesis, Osteopetrosis, T-Lymphocytes, Thymus Gland, Cytokines, Mutagenesis, Bone Remodeling, Gene Targeting, Leukopoiesis, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.